Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Incannex Healthcare Ltd ADR (IXHL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: IXHL (1-star) is a SELL. SELL since 4 days. Simulated Profits (48.65%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -47.52% | Avg. Invested days 21 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 19.05M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.47 | 52 Weeks Range 0.08 - 3.12 | Updated Date 06/29/2025 |
52 Weeks Range 0.08 - 3.12 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.23 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -20952.04% |
Management Effectiveness
Return on Assets (TTM) -76.74% | Return on Equity (TTM) -201.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14183550 | Price to Sales(TTM) 194.37 |
Enterprise Value 14183550 | Price to Sales(TTM) 194.37 | ||
Enterprise Value to Revenue 144.73 | Enterprise Value to EBITDA -5.13 | Shares Outstanding 93695400 | Shares Floating 28234076 |
Shares Outstanding 93695400 | Shares Floating 28234076 | ||
Percent Insiders 26.14 | Percent Institutions 8.29 |
Upturn AI SWOT
Incannex Healthcare Ltd ADR
Company Overview
History and Background
Incannex Healthcare Ltd is an Australian-based pharmaceutical company focused on developing unique medicinal cannabis pharmaceutical products and psychedelic therapies for unmet medical needs. Founded in 2015, it initially focused on medicinal cannabis and has expanded into psychedelic therapies. Milestones include successful clinical trials and partnerships for drug development.
Core Business Areas
- Medicinal Cannabis Therapeutics: Development of cannabinoid-based pharmaceutical products targeting specific medical conditions such as sleep apnea, traumatic brain injury, and anxiety disorders.
- Psychedelic Therapies: Research and development of psychedelic therapies, including psilocybin and MDMA, for the treatment of anxiety, depression, and other mental health conditions.
Leadership and Structure
The company has a board of directors and a management team led by the CEO. The organizational structure includes research and development, clinical operations, and commercial teams.
Top Products and Market Share
Key Offerings
- IHL-42X (Obstructive Sleep Apnea): A proprietary cannabinoid formulation for the treatment of obstructive sleep apnea. Clinical trials are underway. Market share is currently 0% as product is in development stage. Competitors include CPAP devices from ResMed and Philips Respironics, and surgical interventions.
- PsiGAD (Generalized Anxiety Disorder): Psilocybin-assisted psychotherapy for generalized anxiety disorder. Clinical trials are underway. Market share is currently 0% as product is in development stage. Competitors include SSRIs and other anti-anxiety medications from pharmaceutical companies like Pfizer and Eli Lilly, and traditional psychotherapy.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and competition from both generic and branded drugs. The medicinal cannabis and psychedelic therapy markets are rapidly growing, driven by increasing acceptance and legalization.
Positioning
Incannex is positioned as an innovative player in the medicinal cannabis and psychedelic therapy space, focusing on developing novel treatments with strong scientific backing. Its competitive advantage lies in its proprietary formulations and clinical trial programs.
Total Addressable Market (TAM)
The TAM for sleep apnea devices is estimated at around $5 billion. The addressable market for psilocybin-based therapeutics is difficult to accurately estimate at this point, but estimated to be hundreds of millions, based on the TAM of traditional anti-anxiety medication. Incannex's future position is dependent on trial success.
Upturn SWOT Analysis
Strengths
- Proprietary cannabinoid formulations
- Strong focus on clinical trials
- Diversified pipeline of medicinal cannabis and psychedelic therapies
- Experienced management team
Weaknesses
- Limited commercialization experience
- High reliance on clinical trial success
- Significant cash burn rate
- Regulatory uncertainties surrounding cannabis and psychedelics
Opportunities
- Expanding legalization of medicinal cannabis and psychedelics
- Increasing demand for alternative therapies for unmet medical needs
- Potential partnerships with larger pharmaceutical companies
- Advancements in drug delivery technologies
Threats
- Competition from established pharmaceutical companies
- Regulatory setbacks
- Clinical trial failures
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- GWPH
- ACB
- CRON
Competitive Landscape
Incannex faces competition from established pharmaceutical companies and other cannabis and psychedelic therapy developers. Its competitive advantage lies in its proprietary formulations and clinical trial programs focused on specific unmet medical needs.
Growth Trajectory and Initiatives
Historical Growth: The company has experienced growth in its pipeline and market capitalization, driven by successful clinical trial milestones and increasing investor interest in the sector.
Future Projections: Future growth is dependent on the successful completion of clinical trials and regulatory approvals for its lead drug candidates. Analyst estimates vary widely depending on the perceived likelihood of success.
Recent Initiatives: Recent initiatives include expanding its clinical trial programs, forging partnerships with research institutions, and strengthening its intellectual property portfolio.
Summary
Incannex Healthcare is a high-risk, high-reward company focused on novel therapies. Its pipeline is promising, but clinical trial success is critical. The company requires additional funding. Its main focus is advancing its clinical trials while keeping an eye on regulatory developments in the cannabis and psychedelics industries.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Incannex Healthcare Ltd ADR investor relations
- SEC filings
- Market research reports
- Analyst estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The data is based on available information and may be subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Incannex Healthcare Ltd ADR
Exchange NASDAQ | Headquaters Sydney, NSW, Australia | ||
IPO Launch date 2022-03-02 | President, CEO & Executive Director Mr. Joel Bradley Latham | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 9 | Website https://www.incannex.com |
Full time employees 9 | Website https://www.incannex.com | ||
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate in Phase 2 clinical trial to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.